1. Home
  2. CYCC vs NAOV Comparison

CYCC vs NAOV Comparison

Compare CYCC & NAOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYCC
  • NAOV
  • Stock Information
  • Founded
  • CYCC 1992
  • NAOV 2003
  • Country
  • CYCC United States
  • NAOV United States
  • Employees
  • CYCC 12
  • NAOV N/A
  • Industry
  • CYCC Biotechnology: Pharmaceutical Preparations
  • NAOV Industrial Specialties
  • Sector
  • CYCC Health Care
  • NAOV Health Care
  • Exchange
  • CYCC Nasdaq
  • NAOV Nasdaq
  • Market Cap
  • CYCC 2.2M
  • NAOV 1.9M
  • IPO Year
  • CYCC N/A
  • NAOV N/A
  • Fundamental
  • Price
  • CYCC $0.36
  • NAOV $0.50
  • Analyst Decision
  • CYCC Strong Buy
  • NAOV
  • Analyst Count
  • CYCC 1
  • NAOV 0
  • Target Price
  • CYCC $11.00
  • NAOV N/A
  • AVG Volume (30 Days)
  • CYCC 6.4M
  • NAOV 3.6M
  • Earning Date
  • CYCC 11-12-2024
  • NAOV 11-14-2024
  • Dividend Yield
  • CYCC N/A
  • NAOV N/A
  • EPS Growth
  • CYCC N/A
  • NAOV N/A
  • EPS
  • CYCC N/A
  • NAOV N/A
  • Revenue
  • CYCC $74,000.00
  • NAOV $3,291,000.00
  • Revenue This Year
  • CYCC N/A
  • NAOV N/A
  • Revenue Next Year
  • CYCC $88.68
  • NAOV N/A
  • P/E Ratio
  • CYCC N/A
  • NAOV N/A
  • Revenue Growth
  • CYCC N/A
  • NAOV 227.79
  • 52 Week Low
  • CYCC $0.31
  • NAOV $0.44
  • 52 Week High
  • CYCC $4.00
  • NAOV $1.52
  • Technical
  • Relative Strength Index (RSI)
  • CYCC 43.22
  • NAOV 42.05
  • Support Level
  • CYCC $0.34
  • NAOV $0.44
  • Resistance Level
  • CYCC $0.39
  • NAOV $0.65
  • Average True Range (ATR)
  • CYCC 0.08
  • NAOV 0.13
  • MACD
  • CYCC 0.00
  • NAOV -0.01
  • Stochastic Oscillator
  • CYCC 6.30
  • NAOV 6.78

About CYCC Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

About NAOV NanoVibronix Inc.

NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.

Share on Social Networks: